Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ostrov

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
BMC Cancer|July 12, 2013
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growthVita M Golubovskaya, Baotran Ho, Min Zheng, et al.
Physiological Reports|June 24, 2022
Durability of and role of AKT in FGF7p urothelial protection against cyclophosphamideSridhar Tatarao Narla, Lori Rice, David Ostrov, et al.
Immunohorizons|August 25, 2025
Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren's disease in the mouse modelAlexandria Voigt, Shivai Gupta, Yiran Shen, et al.
Research Square|July 18, 2025
The ExoGAN generative AI framework enables extracellular vesicle-based immunotherapyKiley Graim, Zachary Greenberg, Tina Salehi Torabi, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 2, 2012
A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivoVita M Golubovskaya, Nadia L Palma, Min Zheng, et al.
Biochemical and Biophysical Research Communications|August 12, 2009
Targeting of the protein interaction site between FAK and IGF-1RDonghang Zheng, Elena Kurenova, Deniz Ucar, et al.
Molecular Carcinogenesis|November 4, 2009
A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenograftsDonghang Zheng, Vita Golubovskaya, Elena Kurenova, et al.
The Journal of Biological Chemistry|August 28, 2009
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanismPatrick Corsino, Nicole Horenstein, David Ostrov, et al.
Plos One|January 14, 2020
The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDACMatthew Brown, Wanbin Zhang, Deyue Yan, et al.
Cell Cycle (Georgetown, Tex.)|July 3, 2009
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancerSteven N Hochwald, Carl Nyberg, Min Zheng, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
BMC Cancer|July 12, 2013
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growthVita M Golubovskaya, Baotran Ho, Min Zheng, et al.
Physiological Reports|June 24, 2022
Durability of and role of AKT in FGF7p urothelial protection against cyclophosphamideSridhar Tatarao Narla, Lori Rice, David Ostrov, et al.
Immunohorizons|August 25, 2025
Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren's disease in the mouse modelAlexandria Voigt, Shivai Gupta, Yiran Shen, et al.
Research Square|July 18, 2025
The ExoGAN generative AI framework enables extracellular vesicle-based immunotherapyKiley Graim, Zachary Greenberg, Tina Salehi Torabi, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 2, 2012
A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivoVita M Golubovskaya, Nadia L Palma, Min Zheng, et al.
Biochemical and Biophysical Research Communications|August 12, 2009
Targeting of the protein interaction site between FAK and IGF-1RDonghang Zheng, Elena Kurenova, Deniz Ucar, et al.
Molecular Carcinogenesis|November 4, 2009
A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenograftsDonghang Zheng, Vita Golubovskaya, Elena Kurenova, et al.
The Journal of Biological Chemistry|August 28, 2009
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanismPatrick Corsino, Nicole Horenstein, David Ostrov, et al.
Plos One|January 14, 2020
The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDACMatthew Brown, Wanbin Zhang, Deyue Yan, et al.
Cell Cycle (Georgetown, Tex.)|July 3, 2009
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancerSteven N Hochwald, Carl Nyberg, Min Zheng, et al.
Pageof 3